The company develops immunotherapy drugs utilizing a proprietary antibody technology platform to target and treat various cancers and autoimmune diseases. Its lead candidates, A-319 and A-337, are currently in clinical phase I studies, with additional drug molecules in preclinical development stages.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers and autoimmune diseases lack effective treatments, creating a significant unmet medical need. Traditional therapies often have limited efficacy or severe side effects, highlighting the need for more targeted and innovative approaches.
Solution
The company is developing a pipeline of novel immunotherapy drugs designed to target and treat various cancers and autoimmune diseases. Their approach leverages a proprietary antibody technology platform to create highly specific therapeutics. These antibodies are engineered to modulate the immune system, enhancing its ability to recognize and eliminate cancer cells or suppress autoimmune responses. The company's lead drug candidates are currently undergoing clinical trials to assess their safety and efficacy.
Target Audience
The primary target audience includes patients suffering from various cancers and autoimmune diseases, as well as healthcare providers seeking more effective treatment options.
Features
- Proprietary antibody technology platform for generating highly specific therapeutic antibodies
- Lead drug candidates A-319 and A-337 currently in Phase I clinical trials
- Additional drug molecules in preclinical development stages
- Focus on developing immunotherapies for both cancer and autoimmune diseases